NCT06181019

Acupuncture Combined With Mirabegron in the Treatment of OAB

Acupuncture Combined With Mirabegron in the Treatment of Overactive Bladder Syndrome: A Prospective Randomized Controlled Trial

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 75 (actual)
• Sponsor: The Affiliated Ganzhou Hospital of Nanchang University · Academic / Other
• Sex: All
• Age: 14 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Introduction: As conventional treatments for overactive bladder (OAB) have not yet shown satisfactory results, new approaches are needed. Therefore, this study aimed to investigate the efficacy and safety of acupuncture combined with mirabegron for the treatment of OAB. Methods: This prospective cohort study enrolled 80 OAB patients who were then divided into control and treatment groups using a randomized number-table method. The control group was administered mirabegron alone (50 mg/day), while the treatment group was administered mirabegron orally along with acupuncture at the following points: guanyuan (CV4), zhongji (CV3), and sanyinjiao (SP6). The OAB symptom score (overactive bladder syndrome score \[OABSS\]), voiding, urgency, nocturia, incontinence, and incidence of related adverse events were compared between the two groups at baseline and after 4, 8, and 12 weeks of treatment.

Conditions

• Overactive Bladder

Interventions

Type	Name	Description
DRUG	50 mg of mirabegron	Patients in the control group were treated with 50 mg of mirabegron (Astellas Pharma, Tokyo, Japan) for 12 weeks.
COMBINATION_PRODUCT	acupuncture combined with mirabegron.	Patients in the treatment group were treated with acupuncture combined with mirabegron.

Timeline

• Start date: 2021-12-01
• Primary completion: 2023-03-31
• Completion: 2024-12-31
• First posted: 2023-12-26
• Last updated: 2023-12-26

Locations

1 site across 1 country: China